Disclaimer: This is a user generated content submitted by a member of the WriteUpCafe Community. The views and writings here reflect that of the author and not of WriteUpCafe. If you have any complaints regarding this post kindly report it to us.

Roots Analysis has done a detailed study on Manufacturing Market Continuous (Small Molecules and Biologics), 2020 – 2030.”, covering key aspects of the industry and identifying future growth opportunities.

To order this 310+ page report, which features 110+ figures and 200+ tables, please visit this – https://www.rootsanalysis.com/reports/view_document/continuous-manufacturing/308.html

Key Market Insights 

  • Eminent representatives from prominent contract service provider companies / organizations are both optimistic and cautious regarding the rising interest in continuous flow technologies, and its adoption
  • Over 60 companies across the globe claim to manufacture drug products / drug substances using the continuous manufacturing technique, either for in-house requirements or for contract service engagements
  • The market landscape features the presence of several well-established players, most of which claim to manufacture small molecules via the continuous technique, and are based in the developed geographies
  • Companies have established continuous drug manufacturing facilities for diverse types of dosage forms in various geographies; Europe and North America have emerged as the key hubs for these facilities
  • Several patents have been filed / granted specifically related to continuous manufacturing of pharmaceutical substances, both industry and non-industry players are actively involved in such efforts
  • Organizations have also extended financial support to aid the research efforts being put by various stakeholders in this domain; the current focus is on investigation of continuous manufacturing technologies
  • Over time, there has been a lot of activity in this arena, including the establishment of several partnerships and investments in capability and capacity expansions and new facilities worldwide
  • Most of the continuous manufacturing capacity belongs to established companies (in-house manufacturers and CMOs), accounting for over 70% of the available capacity across various geographies
  • Involvement of various other stakeholders including continuous equipment providers and modular facility providers is likely to revolutionize the overall manufacturing domain
  • As the adoption of continuous manufacturing technologies increases, the market is likely to witness significant growth; in the short term, majority of service-based revenues is likely to come from drug product related projects

For more information, please visit https://www.rootsanalysis.com/reports/view_document/continuous-manufacturing/308.html

 

Table of Contents

 

TABLE OF CONTENTS

 

1.         PREFACE         

1.1.       Scope of the Report

1.2.       Research Methodology

1.3.       Chapter Outlines

 

2.         EXECUTIVE SUMMARY

 

3.         INTRODUCTION

3.1.       Chapter Overview

3.2.       Historical Evolution of Continuous Manufacturing 

3.3.       Continuous Manufacturing in the Pharmaceutical Industry

3.3.1.    Regulatory Landscape 

3.3.2.    Early Adopters of Continuous Manufacturing

3.3.3.    Anticipated Shift to Continuous Manufacturing

3.3.4.    Advantages of Continuous Manufacturing

3.3.5.    Key Challenges Associated with Continuous Manufacturing

3.3.6.    Future Perspectives

 

4.         MARKET LANDSCAPE

4.1.       Chapter Overview

4.2.       Companies with Expertise in Continuous Manufacturing: Overall Market Landscape

4.2.1.    Analysis by Year of Establishment

4.2.2.    Analysis by Company Size

4.2.3.    Analysis by Purpose of Manufacturing

4.2.4.    Analysis by Scale of Operation

4.2.5.    Analysis by Location of Headquarters

4.2.6.    Analysis by Location of Continuous Manufacturing Facilities

4.2.7.    Analysis by Type of Drug Molecule

4.2.8.    Analysis by Type of Continuous Manufacturing Related Service

4.2.9.    Analysis by Type of Dosage Form

4.2.10.  Heat Map: Analysis by Company Size and Location of Headquarters

4.2.11.  Information on Production Capacity

4.2.12.  Logo Landscape: Analysis by Year of Establishment and Company Size  

4.2.13.  Grid Representation: Analysis by Scale of Operation, Type of Continuous Manufacturing Related Service and Type of Dosage Form

4.2.14.  Geographical Map: Analysis by Location of Continuous Manufacturing Facilities and Type of Drug Molecule

 

5.         COMPANIES WITH EXPERTISE IN CONTINUOUS MANUFACTURING IN NORTH AMERICA: PROFILES

5.1.       Chapter Overview

5.2.       AbbVie Contract Manufacturing

5.2.1.    Company Overview

5.2.2.    Service Portfolio

5.2.3.    Continuous Manufacturing Capabilities and Facilities

5.2.4.    Recent Developments and Future Outlook

 

5.3.       Cambrex

5.3.1.    Company Overview

5.3.2.    Service Portfolio

5.3.3.    Continuous Manufacturing Capabilities and Facilities

5.3.4.    Recent Developments and Future Outlook

 

5.4.       Patheon

5.4.1.    Company Overview

5.4.2.    Service Portfolio

5.4.3.    Continuous Manufacturing Capabilities and Facilities

5.4.4.    Recent Developments and Future Outlook

 Roots Analysis
A430, 4th Floor,
Bestech Business Towers, Sector 66, Mohali, India
sales@rootsanalysis.com
+1 (415) 800 3415
+44 (122) 391 1091
Web: https://www.rootsanalysis.com/
LinkedIn: https://in.linkedin.com/company/roots-analysis
Twitter: https://twitter.com/RootsAnalysis

Login

Welcome to WriteUpCafe Community

Join our community to engage with fellow bloggers and increase the visibility of your blog.
Join WriteUpCafe